Document Detail


Diarsenic and tetraarsenic oxide inhibit cell cycle progression and bFGF- and VEGF-induced proliferation of human endothelial cells.
MedLine Citation:
PMID:  15723287     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Arsenic trioxide (As2O3, diarsenic oxide) has recently been reported to induce apoptosis and inhibit the proliferation of various human cancer cells derived from solid tumors as well as hematopoietic malignancies. In this study, the in vitro effects of As2O3 and tetraasrsenic oxide (As4O6) on cell cycle regulation and basic fibroblast growth factor (bFGF)- or vascular endothelial growth factor (VEGF)-stimulated cell proliferation of human umbilical vein endothelial cells (HUVEC) were investigated. Significant dose-dependent inhibition of cell proliferation was observed when HUVEC were treated with either arsenical compound for 48 h, and flow cytometric analysis revealed that these two arsenical compounds induced cell cycle arrest at the G1 and G2/M phases--the increases in cell population at the G1 and G2/M phase were dominantly observed in As2O3- and As4O6-treated cells, respectively. In both arsenical compounds-treated cells, the protein levels of cyclin A and CDC25C were significantly reduced in a dose-dependent manner, concomitant to the reduced activities of CDK2- and CDC2-associated kinase. In G1-synchronized HUVEC, the arsenical compounds prevented the cell cycle progression from G1 to S phase, which was stimulated by bFGF or VEGF, through the inhibition of growth factor-dependent signaling. These results suggest that arsenical compounds inhibit the proliferation of HUVEC via G1 and G2/M phase arrest of the cell cycle. In addition, these inhibitory effects on bFGF- or VEGF-stimulated cell proliferation suggest antiangiogenic potential of these arsenical compounds.
Authors:
Sang Hyeok Woo; Myung-Jin Park; Sungkwan An; Hyung-Chahn Lee; Hyeon-Ok Jin; Su-Jae Lee; Ho-Shin Gwak; In-Chul Park; Seok-Il Hong; Chang Hun Rhee
Related Documents :
15659447 - Cell cycle dependence of elicitor-induced signal transduction in tobacco by-2 cells.
1980597 - Cell-cycle regulation of insulin-stimulated tyrosine aminotransferase activity in rat h...
7911457 - Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and...
1932357 - Automatic classification of cells in cell cycle phases based on ki-67 antigen quantific...
23252897 - Targeting plasma cells with proteasome inhibitors: possible roles in treating myastheni...
23449477 - Polymeric delivery of sirna for dual silencing of mcl-1 and p-glycoprotein and apoptosi...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cellular biochemistry     Volume:  95     ISSN:  0730-2312     ISO Abbreviation:  J. Cell. Biochem.     Publication Date:  2005 May 
Date Detail:
Created Date:  2005-04-18     Completed Date:  2005-08-18     Revised Date:  2007-05-02    
Medline Journal Info:
Nlm Unique ID:  8205768     Medline TA:  J Cell Biochem     Country:  United States    
Other Details:
Languages:  eng     Pagination:  120-30     Citation Subset:  IM    
Copyright Information:
2005 Wiley-Liss, Inc
Affiliation:
Laboratory of Cell Biology, Korea Institute of Radiological & Medical Sciences, Seoul 139-706, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / pharmacology*
Arsenicals / pharmacology*
Cell Proliferation / drug effects*
Cells, Cultured
Dose-Response Relationship, Drug
Endothelial Cells / metabolism*
Fibroblast Growth Factor 2 / pharmacology*
Humans
Neoplasms / drug therapy,  physiopathology
Oxides / pharmacology*
Vascular Endothelial Growth Factor A / pharmacology*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Arsenicals; 0/Oxides; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 0/arsenic tetraoxide; 103107-01-3/Fibroblast Growth Factor 2; 1327-53-3/arsenic trioxide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sexual dimorphism of growth plate prehypertrophic and hypertrophic chondrocytes in response to testo...
Next Document:  Is multicenter collaborative research in clinical genetics dead and, if so, what killed it?